We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 4 of 6 for:    aerpio

Single Ascending Dose Study to Assess the Safety, Tolerability, PK and PD Effects in Male Volunteers

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02914262
First Posted: September 26, 2016
Last Update Posted: March 16, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Aerpio Therapeutics
  Purpose
This will be a double-blind, randomized, placebo-controlled, single ascending dose, Phase I study in healthy male subjects.

Condition Intervention Phase
IBD Drug: AKB-4924 Other: Placebo Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Phase 1a Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of AKB 4924 in Healthy Male Volunteers

Further study details as provided by Aerpio Therapeutics:

Primary Outcome Measures:
  • Single ascending dose (SAD): Safety and tolerability of AKB-4924 [ Time Frame: 8 days after a single oral dose ]
    Safety evaluation will study the adverse event (AE) profile, clinical laboratory safety tests, vital signs and ECG monitoring


Enrollment: 40
Study Start Date: August 2016
Study Completion Date: January 2017
Primary Completion Date: November 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Experimental:Cohort 1-6 Experimental
Intervention AKB 4924 Six subjects per cohort will receive single doses of 20 to up to 480 mg of AKB 4924 orally in a dose escalation format
Drug: AKB-4924
Comparison of different dosages of AKB-4924
Other Name: AKB-4924 Cohort 1-6
Placebo Comparator: Placebo:Cohort 1-6

Intervention Placebo:

Two subjects per cohort will receive single oral doses of placebo

Other: Placebo
Placebo comparator
Other Name: Placebo Cohort 1-5

Detailed Description:
Single oral doses of AKB-4924 will be investigated in up to 6 sequential cohorts of 8 healthy male subjects. Primarily 6 dose levels are planned; the proposed doses are 20 mg, 60 mg, 120 mg, 240 mg, 360 mg, and 480 mg. Actual doses may be decreased or increased based on the safety and tolerability of the drug, as determined by the Investigator and Sponsor. Additional cohorts may be added as needed to test lower, higher, or repeat doses.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 49 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Healthy male subjects between 18 to 49 years of age, inclusive.
  2. Body mass index (BMI) between 18 to 30 kg/m2, inclusive.
  3. Understands the procedures and requirements of the study and provides written informed consent and authorization for protected health information disclosure.

Exclusion Criteria:

  1. Non-vasectomized male subjects and their female partners who are unable or unwilling to use an acceptable method of contraception (as described in Section 8.1.3, Contraception and Pregnancy Avoidance Measures) during the study and for 30 days following the last dose of study medication.
  2. Evidence of active infection, unless the medical monitor and Investigator agree that the subject is appropriate for this study.
  3. Current or past history of chronic disease including, but not limited to, gastrointestinal, cardiovascular, cerebrovascular, pulmonary, neurologic, renal, or liver disease.
  4. Diastolic blood pressure ≤55 mmHg or systolic blood pressure ≤100 mmHg at Screening.
  5. Clinically important or significant conduction abnormalities on ECG at Screening (including QTcF intervals >450 msec) and/or history of long QT syndrome. It is acceptable to repeat the ECG to confirm findings.
  6. Any history of malignancy in the previous 5 years except for curatively resected basal cell carcinoma of skin or squamous cell carcinoma of skin, or resected benign colonic polyps.
  7. Seropositive for human immunodeficiency virus (HIV), Hepatitis B surface antigen (HBsAg), or Hepatitis C virus (HCV) antibodies.
  8. Serum transaminase (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]) levels >1.5X the upper limit of normal (ULN). If a subject presents with an abnormal AST and/or ALT results, the subject may be re-scheduled or the test may be repeated once at the discretion of the Investigator.
  9. Serum creatinine level ≥1.50 mg/dL. It is acceptable to repeat the test to confirm findings.
  10. Chronic daily medication use, except once daily over the counter multi-vitamin supplement.
  11. Subject has taken any prescription medication within 7 days (or 5 half-lives, whichever is longer) prior to admission to the CRU.
  12. Herbal supplements within 48 hours prior to dosing of study drug.
  13. History of regular alcohol consumption exceeding 14 drinks/week (1 drink = 5 ounces of wine or 12 ounces [360 mL] of beer or 1.5 ounces [45 mL] of hard liquor) within 6 months of Screening.
  14. Any history of alcohol or drug dependence within the previous year prior to Screening. Self-reported substance or alcohol dependence (excluding nicotine or caffeine) within the past 2 years, and/or have ever been in a substance or alcohol rehabilitation program to treat their substance or alcohol dependence
  15. Any use of alcohol within 48 hours of admission to the CRU.
  16. Consumption of foods or beverages containing caffeine from 24 hours prior to dosing until the last sample collected during the Treatment period.
  17. Subjects with a known history of smoking and/or has used nicotine or nicotine-containing products within the past 6 months.
  18. Positive screen for drugs of abuse or a positive alcohol or cotinine result at screening or Day 1.
  19. Donation of blood or blood products during the 4 weeks prior to dosing of study drug.
  20. Physical activity greater than the normal level of activity from 48 hours prior to admission to the CRU.
  21. Use of an investigational medication or device or participation in an investigational study within 30 days or 5 half-lives of the investigational medication, whichever is longer, preceding Day 1, or ongoing or scheduled participation in another investigational study during the present study through the Day 8 Follow-Up.
  22. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the Investigator's judgment, would make the subject inappropriate for study entry.
  23. Known allergy to HPβCD.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02914262


Locations
Canada
INC Research
Toronto, Canada
Sponsors and Collaborators
Aerpio Therapeutics
Investigators
Principal Investigator: Michael McDonnell, MD INC Research
  More Information

Responsible Party: Aerpio Therapeutics
ClinicalTrials.gov Identifier: NCT02914262     History of Changes
Other Study ID Numbers: AKB-4924-CI-1001
First Submitted: August 16, 2016
First Posted: September 26, 2016
Last Update Posted: March 16, 2017
Last Verified: March 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No